Feasibility and Acceptability of Group Medical Visits for Anxiety and Depression
NCT ID: NCT06651801
Last Updated: 2025-05-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
20 participants
INTERVENTIONAL
2025-04-15
2025-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Are GMVs feasible and acceptable to patients with depression and anxiety?
This study consists of a pilot RCT with an intervention and control arm. At enrollment, participants will be randomized to the intervention group, 6 months of GMVs, or to the control group, which consists of "standard client services". For the GMV group, participants will engage in a biweekly virtual group that is similar to a standard psychiatric follow-up. Participants in the control group will receive standard care after a psychiatric assessment, which includes follow-up with their primary care provider (family physician or nurse practitioner), individual psychiatric care if suggested by the psychiatrist who did their psychiatric assessment, and/or a referral to publicly funded therapy groups if interested.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Single-Session Intervention Targeting Emotional Awareness, Clarity, and Acceptance to Reduce Depression/Anxiety
NCT05109507
The Acceptability and Effectiveness of Stepped Care Psychoeducation Classes in Rural Manitoba
NCT04105790
Single Session Intervention to Prevent Common Mental Disorders and Among College Students
NCT04267068
Acceptability/Feasibility of IU Intervention
NCT05172427
Mindful Self-compassion for Anxiety and Depression: Impact of Delivery Method
NCT07028216
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard client services
Participants will follow-up with their primary care provider (family physician or nurse practitioner).
No interventions assigned to this group
Virtual outpatient care
Group Medical Visits
Group medical visits occur every 2 weeks virtually (via Zoom) for 6 months. Each group consists of 45 minutes of group time and 5 minute individual check-in appointments. The group time consists of psychoeducation, group support, and medication follow-up.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Group Medical Visits
Group medical visits occur every 2 weeks virtually (via Zoom) for 6 months. Each group consists of 45 minutes of group time and 5 minute individual check-in appointments. The group time consists of psychoeducation, group support, and medication follow-up.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to participate in English language group with up to 10 participants
* Able to commit to a virtual biweekly group for about 1.5 hours each group
* Able to do virtual group from a private location with camera access
* Live in community in Manitoba and plan to stay for 6-month period
Exclusion Criteria
* Patients who already have established longitudinal care with a psychiatrist
* Received ECT treatment within past 6 months
* Any diagnosis that would significantly impact ability to participate in the group. For example:
* Moderate-to-severe substance use disorders (in particular substance use throughout day or inability to attend group without using substances before)
* Current psychotic symptoms
* Moderate-to-severe intellectual disability or neurocognitive disorder
* Current significant eating disorder symptoms (for example resulting in significant weight loss/malnutrition or that take up a significant part of the day either mentally or physically)
* Self harm behaviour requiring medical/psychiatric attention or active suicidal ideation/suicide attempts within the past 6 months
* Concern about safety of other group members/facilitators if this patient were to join
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Manitoba
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kirsten Penner-Goeke
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
PsycHealth Centre
Winnipeg, Manitoba, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HS26533
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.